Pancreatic islet cells (None)

Pancreatic islet cells are the endocrine units of the pancreas, primarily composed of insulin-producing beta cells and glucagon-producing alpha cells, which work in concert to maintain physiological glucose homeostasis (StatPearls, 2023). Transplantation of these cells is a therapeutic strategy for patients with Type 1 Diabetes Mellitus, particularly those with brittle diabetes or severe hypoglycemic unawareness (NIH/NIDDK, 2023). The procedure involves isolating islets from a deceased donor's pancreas and infusing them into the recipient's portal vein, where they lodge in the liver and begin secreting insulin in response to blood sugar levels (PubMed, PMID: 10903358). While this approach can achieve insulin independence and significantly improve glycemic control, it is not a single molecular target but a complex cellular therapy. Success is often monitored via C-peptide levels and HbA1c reduction, which indicate the functional mass of the transplanted beta cells. However, challenges remain, including the requirement for lifelong immunosuppression with drugs like tacrolimus and sirolimus to prevent autoimmune and alloimmune destruction of the graft (The Lancet, 2006). Additionally, the scarcity of donor organs and the potential for procedural complications like portal vein thrombosis limit the widespread application of this therapy.

Other names

Islets of LangerhansPancreatic endocrine cellsIslet transplantBeta cellsAlpha cells

Restoration of endogenous insulin and glucagon secretion to maintain normoglycemia through a physiological bio-feedback loop.